Sanofi $SNY Stock: EagleClaw Capital Managment LLC Reduces Stake

EagleClaw Capital Managment LLC cut its holdings in shares of Sanofi (NASDAQ:SNY) by 60.6% in the 3rd quarter, Holdings Channel reports. The firm owned 17,875 shares of the company’s stock after selling 27,535 shares during the period. EagleClaw Capital Managment LLC’s holdings in Sanofi were worth $737,000 at the end of the most recent reporting period.

A number of other large investors have also recently added to or reduced their stakes in SNY. Bank of America Corp DE grew its position in Sanofi by 11.0% in the first quarter. Bank of America Corp DE now owns 9,484,350 shares of the company’s stock worth $456,956,000 after buying an additional 940,342 shares during the last quarter. Mondrian Investment Partners LTD lifted its position in shares of Sanofi by 2.3% during the 3rd quarter. Mondrian Investment Partners LTD now owns 5,652,139 shares of the company’s stock valued at $233,038,000 after acquiring an additional 129,575 shares during the last quarter. Royal Bank of Canada lifted its position in shares of Sanofi by 17.5% during the 1st quarter. Royal Bank of Canada now owns 3,155,080 shares of the company’s stock valued at $152,011,000 after acquiring an additional 470,882 shares during the last quarter. Equity Investment Corp lifted its position in shares of Sanofi by 1.3% during the 3rd quarter. Equity Investment Corp now owns 2,636,859 shares of the company’s stock valued at $108,718,000 after acquiring an additional 34,888 shares during the last quarter. Finally, Regal Partners Ltd boosted its stake in shares of Sanofi by 33.2% during the 1st quarter. Regal Partners Ltd now owns 2,545,432 shares of the company’s stock worth $122,639,000 after acquiring an additional 633,782 shares in the last quarter. 14.03% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

A number of equities analysts recently issued reports on SNY shares. UBS Group restated a “neutral” rating on shares of Sanofi in a report on Thursday, September 17th. Wall Street Zen raised Sanofi from a “hold” rating to a “buy” rating in a report on Saturday, November 7th. Royal Bank Of Canada initiated coverage on Sanofi in a research report on Tuesday, September 8th. They issued a “sector perform” rating for the company. HSBC reiterated a “buy” rating on shares of Sanofi in a research report on Thursday, September 10th. Finally, BNP Paribas Exane raised Sanofi from a “neutral” rating to an “outperform” rating and set a $57.00 price target on the stock in a research note on Monday. One investment analyst has rated the stock with a Strong Buy rating, eight have assigned a Buy rating and twelve have given a Hold rating to the stock. Based on data from MarketBeat, Sanofi has an average rating of “Hold” and an average target price of $53.00.

Sanofi Stock Down 0.2%

Shares of NASDAQ:SNY opened at $48.37 on Friday. The company has a debt-to-equity ratio of 0.20, a quick ratio of 0.27 and a current ratio of 1.12. The company has a market cap of $117.27 billion, a PE ratio of 23.95, a price-to-earnings-growth ratio of 1.33 and a beta of 0.31. Sanofi has a 52 week low of $39.07 and a 52 week high of $52.67. The firm has a 50 day simple moving average of $42.68 and a 200 day simple moving average of $44.38.

Sanofi (NASDAQ:SNY) last posted its quarterly earnings data on Friday, October 30th. The company reported $2.04 EPS for the quarter, topping analysts’ consensus estimates of $1.56 by $0.48. Sanofi had a net margin of 8.70% and a return on equity of 15.16%. The firm had revenue of $17.25 billion during the quarter, compared to analyst estimates of $14.30 billion. During the same quarter last year, the business posted $2.91 EPS. The company’s revenue was up 16.2% on a year-over-year basis. As a group, research analysts expect that Sanofi will post 5.07 earnings per share for the current year.

Sanofi Company Profile

Sanofi is a France-based global biopharmaceutical company that researches, develops, manufactures and markets medicines and vaccines. Its work spans areas including immunology, oncology, rare diseases and neurology, as well as preventive vaccines. The company’s portfolio includes Dupixent, an immunology medicine developed with Regeneron, and vaccines for diseases such as influenza and meningitis. Sanofi serves patients and healthcare providers in markets around the world. Sanofi traces its origins to a company established in France in 1973.